Therapeutics: Receptor-interacting serine-threonine kinase 1 (RIPK1; RIP1); RIPK3 (RIP3); mixed-lineage kinase domain-like (MLKL)

Cardiovascular disease

INDICATION: Atherosclerosis

Patient sample and mouse studies suggest inhibiting the necroptosis-related proteins RIPK1, RIPK3 or

Read the full 152 word article

How to gain access

Continue reading with a
two-week free trial.